Connect, collaborate, and make a difference

At MSD, we are unified around our purpose of using the power of leading-edge science to save and improve lives around the world. For more than a century, MSD has been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for some of the world's most challenging diseases.

In oncology, MSD is committed to advancing breakthrough innovations that help extend the lives of patients with certain types of cancer. Our global oncology research spans more than 30 types of cancer, reflecting our continued efforts to expand treatment possibilities and improve outcomes for patients.

MSD also works to strengthen the global fight against infectious diseases through vaccines and resilient immunisation programmes that improve knowledge, confidence and access to vaccination. In hospital, specialty and chronic care, MSD continues to pursue solutions for unmet needs in areas including HIV, infectious diseases and cardiovascular disease.

Novartis Malaysia has a long heritage and legacy in the country. Established in 1971, Novartis Malaysia is a leading multinational company with over 600 employees across the Novartis International division and the Novartis Corporate Center Kuala Lumpur (NOCC KL), which delivers enterprise and regional services to 24 countries including Novartis headquarters in Basel. Through its over 50-year presence in Malaysia, Novartis Malaysia continues to deliver on its corporate purpose of reimagining medicine to improve and extend the lives of over 35 million Malaysians.

In 2022, Novartis Malaysia was recognized as Sponsor of the Year by Clinical Research Malaysia for initiating 24 new clinical trials and has built a strong track record of expanding access to innovative medicines through collaborations with the Ministry of Health, touching the lives of more than 1.7 million Malaysian patients.

Most recently, Novartis Malaysia earned the Great Place to Work (GPTW) Certification for 2025/2026, with 85% of employees affirming it as a great place to work, reflecting a workplace culture grounded in trust, flexibility, inclusion, and purpose-driven careers. Novartis Malaysia is also recognized as one of Malaysia's top ten Best Workplaces in 2026, underscoring the organization's commitment to creating an environment where associates feel supported, valued, and empowered to thrive.

Berjaya Corporation Berhad (“BCorp”) is a leading Malaysian conglomerate with roots tracing back to 1984, when its Founder and Advisor, Tan Sri Dato' Seri Vincent Tan Chee Yioun, acquired a controlling stake in Berjaya Kawat Berhad. Through a series of strategic restructurings, including the formation of Berjaya Group Berhad in 1988 and the listing of BCorp on Bursa Malaysia in 2006, the Group evolved into a diversified multinational enterprise.

Today, Berjaya operates across a wide range of industries, including retail, property development and investment, hospitality, financial services, food and beverage, gaming and lottery management, automotive distribution, telecommunications, environmental services, clean technology, and digital solutions. Its diverse portfolio reflects a commitment to sustainable growth, innovation, and long-term value creation.

Guided by a vision to build profitable, responsible, and future-ready businesses, Berjaya emphasises operational excellence, customer value, and empowerment of its people. The Group integrates Environmental, Social and Governance (ESG) principles and Corporate Social Responsibility (CSR) initiatives into its business strategy, demonstrating its commitment to creating positive impacts for communities, stakeholders, and the environment while driving continued growth and success.

NOVUGEN in addition to being USFDA-accredited and based in Malaysia, has also helped to accelerate difficult to make products by being the first to market medications in Malaysia like Pazopanib, Sacubitril + Valsartan, Dapagliflozin, Amlodipine + Valsartan, Amlodipine + Telmisartan, Sitagliptin + Metformin, Midodrine, Atorvastatin + Ezetimibe, Vonoprazan, Tadalafil 5mg to name a few. We have exported to the USA and are now in the process of registering in 19 other countries.

Roche is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Roche has been present in Malaysia since 1972, when the sales and distribution of products was managed by a third party distributor. Since then, Roche has established its operations to include Roche (Malaysia) Sdn. Bhd., Roche Diagnostics (Malaysia) Sdn. Bhd. and Roche Services (Asia Pacific) Sdn. Bhd. With over 1,000 employees, Roche has grown into one of the leading healthcare companies in Malaysia that provides holistic healthcare solutions to healthcare practitioners and patients. For more information, visit www.roche.com.my

Sandoz is a global leader in generic medicines and a pioneer in biosimilars, driven by its purpose of pioneering access for patients. As one of the world's leading providers of off-patent medicines, Sandoz plays a critical role in improving access to high-quality, affordable healthcare while supporting the sustainability of healthcare systems worldwide. Off-patent medicines account for approximately 80% of prescribed treatments globally, making Sandoz an important partner in helping patients receive the treatments they need while reducing healthcare costs. Sandoz develops and delivers trusted medicines that meet the highest quality standards, from research and development through manufacturing and supply.

In Malaysia, Sandoz has been serving patients and healthcare professionals for more than 50 years. The company offers treatments across key therapeutic areas and works closely with healthcare partners to improve patient access to essential medicines. Sandoz Malaysia achieved a significant milestone by introducing the country's first biosimilar for cancer treatment, reinforcing its commitment to advancing patient care. Based in Selangor, the Malaysia office also serves as a regional hub for the Sandoz Asia Cluster, with more than 100 local and regional professionals dedicated to making a meaningful difference for patients every day.

Pfizer Malaysia is the Malaysian affiliate of Pfizer, a global biopharmaceutical company dedicated to delivering breakthroughs that change patients' lives. With a presence in Malaysia since 1964, Pfizer has been supporting the country's healthcare ecosystem for more than 60 years through scientific innovation, partnerships, and healthcare initiatives.

The company focuses on developing and providing innovative medicines and vaccines across therapeutic areas including oncology, vaccines, internal medicine, and rare diseases. Pfizer Malaysia collaborates with healthcare professionals, government agencies, academic institutions, and patient communities to help improve health outcomes and expand access to quality healthcare.

Guided by our purpose, “Breakthroughs That Change Patients' Lives,” Pfizer Malaysia continues to advance healthcare through science, innovation, and strategic collaborations that address the evolving needs of patients and communities nationwide.